965-52-6
基本信息
硝呋酚酰肼
硝呋齐特
BENZOIC ACID, 4-HYDROXY-, [(5-NITRO-2-FURANYL)METHYLENE]HYDRAZIDE
NIFUROXAZIDE
p-hydroxybenzoic acid (5-nitrofurfurylidene) hydrazide
(nitro-5’furfurylidene-2’)hydroxy-4benzhydrazide
4-hydroxy-benzoicaci((5-nitro-2-furanyl)methylene)hydrazide
diarlidan
dicoferin
ercefurol
ercefuryl
nifuroxazid
p-hydroxy-benzoicaci(5-nitrofurfurylidene)hydrazide
r.c.27-109
NIFUROXAZIDE VETRANAL, 250 MG
4-Hydroxybenzoic acid-[[5-nitro-2-furanyl] methylene] hydrazide
nitrofuroxazide
(5-Nitro-2-furfurylidene)(4-hydroxybenzoyl)hydrazine
4-Hydroxybenzoic Acid 2-[(5-Nitro-2-furanyl)methylene]hydrazide
Adral
Bacifurane
物理化学性质
| 熔点 | 281-283°C |
| 沸点 | 418.17°C (rough estimate) |
| 密度 | 1.3877 (rough estimate) |
| 折射率 | 1.5700 (estimate) |
| 储存条件 | Inert atmosphere,2-8°C |
| 溶解度 | Practically insoluble in water, slightly soluble in ethanol (96 per cent), practically insoluble in methylene chloride. |
| 酸度系数(pKa) | 8.36±0.15(Predicted) |
| 形态 | neat |
| 颜色 | 黄色 |
| BRN | 4264976 |
| 主要应用 | clinical testing |
| InChI | InChI=1S/C12H9N3O5/c16-9-3-1-8(2-4-9)12(17)14-13-7-10-5-6-11(20-10)15(18)19/h1-7,16H,(H,14,17) |
| InChIKey | YCWSUKQGVSGXJO-UHFFFAOYSA-N |
| SMILES | C(NN=CC1=CC=C([N+]([O-])=O)O1)(=O)C1=CC=C(O)C=C1 |
| CAS 数据库 | 965-52-6(CAS DataBase Reference) |
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H312-H332 |
| 防范说明 | P280 |
| WGK Germany | 3 |
| RTECS号 | DH2528300 |
| 存储类别 | 11 - Combustible Solids |
| 毒性 | LD50 intraperitoneal in mouse: 1gm/kg |
应用领域
知名试剂公司产品信息
硝呋酚酰肼价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-B1436R | 硝呋酚酰肼 Nifuroxazide (Standard) | 965-52-6 | 25 mg | 350元 |
| 2026/09/15 | HY-B1436R | 硝呋酚酰肼 Nifuroxazide (Standard) | 965-52-6 | 50 mg | 530元 |
| 2026/09/15 | HY-B1436 | 硝呋酚酰肼 Nifuroxazide | 965-52-6 | 200mg | 500元 |
常见问题列表
| Target | Value |
| STAT1 | |
| STAT3 | |
| STAT5 |
Nifuroxazide是硝基呋喃类化合物抑制剂,抑制STAT转录因子的信号转导。 Nifuroxazide通过减少Jak激酶自身磷酸化阻碍了STAT3组成型磷酸化，从而降低骨髓瘤细胞存活性，而不影响正常的外周血单核细胞。 Nifuroxazide能够降低Jak和TYK2的酪氨酸磷酸化，而对EGF受体酪氨酸激酶或Src激酶没有影响，表明Nifuroxazide对Jak2和TYK2的相对特异性。 Nifuroxazide对 Akt 或 MAPK 磷酸化作用没有抑制。 Nifuroxazide通过减少Jak激酶自身磷酸化抑制STAT3在MM细胞中的组成型磷酸化，并导致STAT3的靶基因Mcl-1下调。 Nifuroxazide会引起包含STAT3活化的初级骨髓瘤细胞和骨髓瘤细胞系的存活性降低，但不影响正常外周血单核细胞。虽然骨髓基质细胞为骨髓瘤细胞提供存活信号，但nifuroxazide会阻断这个生存优势。相对于STAT3与其他细胞通路的相互作用，nifuroxazide与组蛋白去乙酰化酶抑制剂缩肽或MEK抑制剂UO126结合时会显示出更强的细胞毒性。
Compared with the vehicle group, treatment with Nifuroxazide could inhibit tumor growth and tumor weight in a dose-dependent manner, with the inhibition rate of tumor volumes being 43.0% and 62.1% at 25 mg/kg and 50 mg/kg, respectively. It is also shown that Nifuroxazide significantly inhibits the proliferation of nuclear Ki-67-positive cells and induces apoptosis cells of cleaved caspase-3-positive cells. Besides, it is found that treatment with Nifuroxazide could inhibit the expression of MMP-2, MMP-9 and p-Stat3 in A375 tumor tissues. What’s more, Nifuroxazide inhibits the infiltration of MDSCs into the lung, which might be associated with suppression of distant colonization of tumor cells in B16-F10 melanoma metastasis model.